AstraZeneca Plc, the U.K.’s second- biggest drugmaker, is advancing experimental drugs into late- stage clinical trials faster than expected in a bid to replace sales that it’s losing to generic competitors.
It was as close to a Stanley-meets- Livingstone moment as a 21st-century traveler is likely to get. After a weeklong odyssey involving planes, ferries, buses and motorcycles, I peered through sheeting monsoonal rain at a mist- shrouded island.
An experimental drug from Abbott Laboratories and Reata Pharmaceuticals Inc. reversed the decline of kidney function in diabetics in a study that doctors say may lead to a new way of treating chronic kidney disease.
Hospitalizations related to chronic kidney disease are increasing in Australia, spurred by rising rates of Type 2 diabetes, according to a report released today by the Australian Institute of Health and Welfare.